Introduction
Malignant mesothelioma of the tunica vaginalis is an exceedingly rare and aggressive neoplasm. Tunica vaginalis shares a common embryological origin with visceral pleura, peritoneum, and pericardium. 1, 2 Malignant mesothelioma of the tunica vaginalis is morphologically identical to mesothelioma of the peritoneum, 1, 2 however, only 0.3% to 5% of all malignant mesotheliomas arise from this origin. 2 The pathophysiology of these neoplasms remains unclear, and it is difficult to obtain a preoperative diagnosis. Historically, this neoplasm has been associated with a poor prognosis and there are no guidelines for management because of its rarity.
Herein we report a contemporary case series of 7 patients who were diagnosed with malignant mesothelioma of the tunica vaginalis, our experience with early surgical management, and subsequent outcomes.
Cases
Seven cases of histology confirmed malignant mesothelioma of the tunica vaginalis were identified between 2003 and 2014 on retrospective review of the National Institutes of Health (NIH) patient records. Clinical features, history of asbestos exposure, and primary therapeutic approach were collected and verified. Hematoxylin and eosin-stained slides for each case were reviewed with an expert pathologist and the histologic diagnosis of malignant mesothelioma was confirmed using established criteria. The tumors were then subclassified into epithelioid, or biphasic patterns on morphology. Immunohistochemically stains were reviewed. Followup data of patients were obtained by reviewing charts and corresponding with primary physicians.
Clinical Characteristics and Presentation
Clinicopathologic features of the series are summarized in Table 1 . The mean age at diagnosis was 63.6 years (range, 43-85 years). Initial presentation included: 4 (57.1%) hydroceles, 1 (14.3%) solid scrotal mass, 1 (14.3%) with an inguinal mass mimicking an inguinal hernia, and 1 (14.3%) spermatocele. All
Clinical Practice Points
Mesothelioma of the tunica vaginalis is a rare malignancy presenting often as a painless testicular mass. Previous reported cases have described poor prognosis of tunica vaginalis mesothelioma despite aggressive surgery and systemic therapy. Aggressive surgical management should be first-line treatment because more conservative options might increase the risk of recurrence.
There are currently limited data to support the benefit of adjuvant therapies such as radiation or chemotherapy. Post-treatment surveillance is also imperative and should include imaging routinely within the first 2 years. Negative asbestos exposure screening during history should not eliminate clinical suspicion. Case Series of Tunica Vaginalis Mesothelioma patients denied systemic and constitutional symptoms. Two (28.6%) patients reported possible asbestos exposure, and 2 (28.6%) other patients were smokers.
Therapeutic Approach and Pathology
Radical orchiectomy was performed in all patients. Two (28.6%) patients received adjuvant radiotherapy, 1 (14.3%) patient received chemotherapy (pemetrexed and cisplatin) as well as radiation. All patients were followed-up postoperatively with serial imaging to detect for recurrence. Pathologic diagnosis of malignant mesothelioma was confirmed for all 7 patients and are summarized in Table 1 .
Disease Course and Follow-Up All 7 patients were followed-up annually/semiannually with scrotal ultrasound (US) examination, computed tomography (CT) imaging of the chest-abdomen-pelvis, and positron emission tomography/CT imaging to assess for recurrence. One patient developed local recurrence 12 months after primary surgical treatment and eventually passed away of his disease 5 years after initial diagnosis. CT imaging revealed new left-sided mesenteric masses and a poorly defined enhancing soft tissue mass surrounding the vessels within the inguinal canal and scrotum. Another patient was lost to follow-up after his radical orchiectomy. Average length of follow-up (excluding the patient lost to follow-up after discharge) was 52.2 months (range, 15-155 months).
Discussion
The initial clinical presentation of patients in this series coincides with what has been commonly reported in the literature. All of our patients presented with painless scrotal enlargement-spermatocele (14.3%), mass (28.6%), or hydrocele (57.1%). Reported potential risk factors include exposure to asbestos, long-lasting hydrocele, trauma, and herniorrhaphy. Asbestos exposure has the most direct association with malignant mesotheliomas of all variations and has been well documented. 2, 3 Many studies have shown that patients with malignant mesothelioma of the tunica vaginalis have a frequency of asbestos exposure similar to those with pleural mesothelioma, ranging from 34.2% to 41%. 3, 4 However, many of these cases do not specify whether the asbestos exposure was confirmed. Interestingly, only 2 of 7 patients (28.6%) in this case series reported a potential asbestos exposure, which could not be confirmed. All other patients had no risk factor of asbestos exposure on the basis of history. This is much lower than the frequency reported in the literature. As a result, on the basis of these data we believe that a negative asbestos history should not exclude this diagnosis. All patients in this series were referred to the NIH with the suspicion of having testicular malignancy. Diagnosis of malignant mesothelioma of the tunica vaginalis was confirmed on postoperative pathologic examination evaluated at our institution. Historically, the most other reported cases had also confirmed diagnosis postoperatively. 3 Preoperative imaging studies such as scrotal US imaging can be useful, because they might show tunical surface irregularities or soft tissue masses within the tunica vaginalis. 5 Likewise, color Doppler US examination might reveal the vascular characteristics of malignant mesothelioma, although its interpretation can be challenging. 6 Recently there have been case reports of obtaining a correct preoperative diagnosis via US-guided fine-needle aspiration cytology of the suspected scrotal mass. 7 None of the patients in this series received preoperative cytology examination. Radical orchiectomy with complete histologic examination and follow-up for an adequate duration is accepted as the optimal primary treatment option for malignant mesothelioma of the tunica vaginalis. 8 Conservative surgical management such as local resection of the hydrocele wall has been associated with a local recurrence rate of 36% compared with 10.5% to 11.5% reported for radical orchiectomy. 3 All patients in our cohort received radical orchiectomy and none were documented to have had retroperitoneal lymph node dissection. The necessity for lymph node dissection remains controversial. The use of adjuvant therapy in our cohort was dependent on practice patterns at their referring institutions. The role of adjuvant therapy remains inconclusive because of the limited number of reported cases and absence of treatment guidelines. Radiotherapy, chemotherapy, or a combination of both have been used in the past. Cisplatin and pemetrexed has been considered in these patients because of their demonstrated effectiveness in treating pleural mesothelioma. 3, 9 The role in tunica vaginalis-derived mesothelioma is less certain. Plas et al 3 reported that the given data did not strongly support chemotherapy as primary adjuvant therapy. However, because of the rarity of this disease, the numbers supporting this claim are limited. Adjuvant radiotherapy and combined chemotherapy-radiotherapy had slightly more favorable results and were found to be safer to use in patients with locally extended mesothelioma after resection of the tumor with negative margins, and also for patients with disseminated disease who are in good physical condition. 10, 11 Their true therapeutic benefit in the management of this disease has not been fully shown. All patients in this series received radical orchiectomy and none received lymph node dissections. Of the 3 patients who received adjuvant therapy, 2 patients received adjuvant radiotherapy only and the other received adjuvant radiotherapy and chemotherapy with pemetrexed and cisplatin; neither had evidence of disease recurrence in 8 years. However, 3 of the 4 patients who did not receive adjuvant therapy likewise had no evidence of recurrence. Thus, in accordance with the literature, our series does not show a clear benefit to providing adjuvant therapy or necessity for lymph node dissection. Unfortunately, because of the extreme rarity of this disease, robust studies to determine the role of adjuvant therapy are unlikely to ever be successfully completed.
Mesothelioma of the tunica vaginalis testis arises from the serosal membrane of the tunica vaginalis and has a mesenchymal origin. Gross examination often reveals a firm, yellow or white tumor, with a solid or cystic-cut surface. The tunica vaginalis is usually thickened, or it is studded with nodules of varying size. Microscopically, most of the tumors are epithelial with papillary, tubulopapillary, or solid patterns. The neoplastic cells are classically cuboidal with scant to moderate amounts of eosinophilic cytoplasm and bland cytological features in the well differentiated tumors; however, they might appear highly malignant in poorly differentiated tumors. Typically, the papillae have thick, hyalinized fibrovascular cores. Histology of mesothelioma can be categorized into epithelioid, sarcomatoid, or biphasic, with epithelioid being most common. 2 In few cases, the tumors are biphasic with epithelial and sarcomatoid patterns admixed. 12 Prognosis has been reported to be better in epithelioid mesothelioma and worse in sarcomatoid disease. 12 Prognosis in biphasic histology varies on the basis of the mixture of epithelioid and sarcomatoid cells, and is more favorable when there is more epithelioid than sarcomatoid cells. 12 All of the patients in our cohort had epithelioid (Figure 1 ) or biphasic histology. Interestingly, the 1 patient who suffered adverse outcomes had epithelioid histology. The immunohistochemical profile of mesotheliomas that arise from the tunica vaginalis testis is similar to those that arise from the pleura and is typically positive for calretinin, Wilms tumor antibody, D2-40, epithelial membrane antigen, thrombomodulin, and cytokeratin (CK)7, variably positive for CK5/6, and negative for carcinoembryonic antigen and CK20. 13 Historically, patients were found to have a median survival of 23 months and a recurrence rate of 52.5%, with most recurrences occurring within 2 years of follow-up. 3, 4 Age at diagnosis (younger than 60 years old) is the only prognostic factor associated with increased survival (P < .01). 3, 4 In our series, only 1 of 7 (14.3%) had documented recurrence, which occurred 12 months after primary treatment; the patient was diagnosed at age 43 years. These results do not strongly correlate with the existing prognostic data and the disease-free survival is higher than what has been previously reported.
Conclusion
Malignant mesothelioma of the tunica vaginalis is a rare but aggressive malignancy rarely diagnosed preoperatively, and historically associated with a poor prognosis. Absence of a history of asbestos exposure should not rule out this diagnosis if clinical presentation is supportive. Aggressive surgical management should be first-line treatment because more conservative options might increase the risk of recurrence. The patients in our series had a higher disease-free survival and lower rates of recurrence than what has been reported in the literature, which might support the use of aggressive surgery and surveillance for localized cases. 
